After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...